Moderna (MRNA) Stock: Drops 6% in Premarket as Q2 Revenue Rises and Net Loss Hits $782M
TLDR
- Moderna shares drop 6% after quarterly revenue rises slightly to $145 million
- The company narrows its quarterly net loss to $782 million from $825 million
- Moderna cuts its 2026 cost and research spending forecasts by about $200 million
- Norovirus vaccine misses interim success target in an ongoing Phase 3 trial
- FDA decisions for Moderna’s seasonal flu vaccine candidates arrive August 5
Moderna (MRNA) shares fell 6.09% in premarket trading to $54.39 after releasing mixed second-quarter results and reporting a vaccine setback. Revenue rose slightly, while the company narrowed its loss and lowered several expense forecasts. However, the norovirus program missed its interim target.
Q2 Revenue Improves as Expenses Decline
Moderna reported second-quarter revenue of $145 million, up from $142 million one year earlier. United States revenue reached $87 million, while international markets contributed $58 million. United Kingdom deliveries and partnership income offset weaker COVID vaccine sales across several markets.
… Continue reading the full article at the original source below.
This content is automatically aggregated. Full credit goes to the original publisher (coincentral.com).
